Status:
ACTIVE_NOT_RECRUITING
Vaccine Responses in Cancer
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Conditions:
Viral Vaccines
Eligibility:
All Genders
Brief Summary
The investigators are conducting a prospective unblinded study of individuals diagnosed with cancer who will receive one or more of the following: influenza, SARS-CoV2 and shingles.
Detailed Description
Vaccinations are indicated for all adults, but the immunogenicity of vaccination has not been assessed in all situations. In particular, immune responses following vaccination have not been studied in...
Eligibility Criteria
Inclusion
- adults over age 18 who are able to provide consent, who have a diagnosis of cancer, and are willing to receive the influenza, recombinant shingles, and/or SARS-CoV-2 vaccines.
Exclusion
- allergic to influenza, shingles, and/or SARS-CoV-2 vaccination; have HIV infection; have a history of solid organ or bone marrow transplant.
Key Trial Info
Start Date :
November 4 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2028
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT06605625
Start Date
November 4 2022
End Date
October 1 2028
Last Update
October 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104